West Pharmaceutical Services, Inc.
NYSE:WSTMedical - Instruments & Supplies
+$5.04 today
- Market cap
- $28.14B
- Beta
- 1.18
- P/E (TTM)
- 43.6
- EPS (TTM)
- $7.54
- Dividend yield
- 0.26%
Volume 0.59M
Average 0.85M
WST Intangible Assets
Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.
West Pharmaceutical Services, Inc.NYSE: WST
Intangible Assets · Q2 FY2026 · quarter ended Jun 2026
Intangible assets falls 34.0% from a year ago
Intangible assets stood at $6.4M at the end of Q2 FY2026, down 34.0% from a year earlier and down 8.6% from the prior quarter. Over 3 fiscal years it compounded at -25.2% a year.
Context
- Intangible assets amounted to 0.2% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Intangible assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether intangible assets keeps falling in the next quarterly balance sheet after a -34.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Intangible Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.7M USD
- Year-over-year change
- -28.7%
- 4-year CAGR
- -23.9%
| Period | Period end | Intangible Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.7M | -28.7% |
| FY2024 | 2024-12-31 | 10.8M | -28.5% |
| FY2023 | 2023-12-31 | 15.1M | -17.9% |
| FY2022 | 2022-12-31 | 18.4M | -20.0% |
| FY2021 | 2021-12-31 | 23M | — |
Intangible Assets vs competitors
How WST compares with its peers on the latest reported figures
- Peers report in different currencies, so intangible assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -34.0% is the 4th highest of 5, against a peer median of -12.6%.
- Intangible assets amounts to 0.2% of total assets for WST, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $567.67M USD | -18.7% | -13.6% | 14.3% | |
| Jun 2026 | $233.74M USD | -6.5% | -6.8% | 4.6% | |
| Jun 2026 | €38.7M EUR | +15.3% | +4.6% | 1.5% | |
| Jun 2026 | $6.4M USD | -34.0% | -25.2% | 0.2% | |
| Mar 2026 | $3.93M USD | -55.6% | -49.0% | 1.0% | |
| Peer median (excluding WST) | — | -12.6% | -10.2% | 3.0% | |
Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 762.6M | 894.3M | 853.9M | 484.6M | 791.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 489M | 507.4M | 512M | 552.5M | 574.4M |
| Inventory | 378.4M | 414.8M | 434.7M | 377M | 443.9M |
| Other Current Assets | 112M | 103M | 135.8M | 124M | 168.6M |
| Total Current Assets | 1.74B | 1.92B | 1.94B | 1.54B | 1.98B |
| Property, Plant & Equipment (Net) | 1.13B | 1.26B | 1.51B | 1.69B | 1.84B |
| Goodwill | 109.9M | 107.3M | 108.5M | 106.1M | 110M |
| Intangible Assets | 23M | 18.4M | 15.1M | 10.8M | 7.7M |
| Long-term Investments | 207.7M | 204.9M | 210M | 202.1M | 212.3M |
| Tax Assets | 48.5M | 65.6M | 25.7M | 26M | 38.4M |
| Other Non-current Assets | 55.9M | 38.4M | 21.3M | 74.3M | 80.1M |
| Total Non-current Assets | 1.57B | 1.7B | 1.89B | 2.11B | 2.29B |
| Total Assets | 3.31B | 3.62B | 3.83B | 3.64B | 4.27B |
| Account Payables | 232.2M | 215.4M | 242.4M | 239.3M | 253.7M |
| Short-term Debt | 44.2M | 2.2M | 134M | 18.8M | 22.7M |
| Tax Payables | 39.3M | 38.5M | 31M | 50.3M | 0 |
| Deferred Revenue | 48.7M | 57.3M | 41.7M | 49.6M | 0 |
| Other Current Liabilities | 45.1M | 54M | 54.2M | 100.5M | 214.5M |
| Total Current Liabilities | 594.1M | 519M | 671.8M | 550.4M | 654.9M |
| Long-term Debt | 208.8M | 206.7M | 72.8M | 202.6M | 298.4M |
| Deferred Tax Liabilities | 4.9M | 14.3M | 12.7M | 20.5M | 23M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 107.6M | 98.9M | 106.7M | 103.7M | 22.1M |
| Total Non-current Liabilities | 384.3M | 412.9M | 276.7M | 410.7M | 439.1M |
| Total Liabilities | 978.4M | 931.9M | 948.5M | 961.1M | 1.09B |
| Common Stock | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M |
| Retained Earnings | 2.46B | 2.99B | 3.52B | 3.96B | 4.37B |
| Accumulated OCI | (159.6M) | (183M) | (143.8M) | (258.1M) | (105.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | (1) |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 2.34B | 2.68B | 2.88B | 2.68B | 3.18B |
| Total Debt | 325.3M | 317.9M | 309M | 305.3M | 416.7M |
| Net Debt | (437.3M) | (576.4M) | (544.9M) | (179.3M) | (374.6M) |
West Pharmaceutical Services, Inc.
NYSE:WST
Intrinsic Alpha fair value
Locked
Current Price
$404.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.